What recent performance tells you about Pulse Biosciences stock

Pulse Biosciences (PLSE) has drawn attention after a period of strong share price moves, with the stock up about 24% over the past month and about 34% over the past 3 months.

For context, the Miami based bioelectric medicine company has a market value of about US$1.71b and focuses on its nPulse system platform across dermatology and cardiac applications, an area many investors track closely in the healthcare segment.

At a share price of US$25.01, Pulse Biosciences has seen strong recent momentum, with an 86.78% year to date share price return and a 290.78% three year total shareholder return. This comes even though the 7 day share price return is down 3.40%, which can reflect shifting expectations around growth prospects and risk.

If you are looking for other fast moving healthcare names with potential growth stories, it can be useful to scan beyond a single stock using our screener for 37 healthcare AI stocks

With the stock up strongly over recent periods, trading around US$25.01 and sitting below an average analyst price target of US$30.00, the question becomes whether Pulse Biosciences is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 13.7% Overvalued

According to the most followed narrative, Pulse Biosciences has a fair value of $22 per share compared with the recent price of $25.01, which puts expectations in focus.

Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.

Want to see what kind of revenue ramp, margin shift, and valuation multiple that narrative is baking in, and how those pieces fit together over time?

Result: Fair Value of $22 (OVERVALUED)

However, there are still clear risks, including limited current revenue relative to high quarterly costs, as well as the possibility that clinical or reimbursement outcomes fall short of expectations.

Next Steps

With all this in mind, do you think the optimism outweighs the concerns, or the other way around? Act quickly, review the key data points yourself, and then weigh both sides with a closer look at the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If you stop at just one stock, you risk missing other opportunities that might suit your goals even better, so put a few strong alternatives on your radar.

• Target potential mispricings by scanning a focused set of 46 high quality undervalued stocks that pair quality fundamentals with price tags that may warrant a closer look.
• Prioritise resilience by checking out 62 resilient stocks with low risk scores that score well on stability so short term shocks are less likely to derail your plan.
• Spot future contenders early by reviewing the screener containing 22 high quality undiscovered gems that quietly combine solid metrics with less crowded ownership.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.